Levels of P-tau181 and P-tau217 in AD patients’ plasma and CSF start to increase during the pre-symptomatic phase when cortical Aβ fibrils emerge and before insoluble tau tangles can be detected with tau-positron emission tomography48. The gene discussed is MAPT; the disease is Alzheimer disease.